Canada · Delayed Price · Currency is CAD Else Nutrition Holdings Earnings Call Transcripts
Fiscal Year 2026
-
A pioneering plant-based infant nutrition provider highlighted its financial turnaround, regulatory breakthroughs, and strong market positioning. FDA engagement and legislative changes are paving the way for potential U.S. approval, with profitability targeted by early 2027.
Fiscal Year 2025
-
Gross margin surged to 34% in Q3 2025, with operating expenses down 68% year-over-year and monthly cash burn below $200,000. Revenue dipped due to temporary supply issues, but demand remains strong and the company targets cash flow break-even by late 2026 to early 2027.
-
Q2 2025 saw revenue decline due to inventory constraints, but significant cost reductions led to a narrower net loss. Regulatory progress and international expansion efforts continue, with a focus on achieving cash flow break even by late 2026 or early 2027.
-
Q1 2025 saw flat revenues but sharply improved gross margins and reduced operating losses, driven by cost controls and operational efficiencies. U.S. retail presence expanded, while Canadian sales faced setbacks from inventory shortages. Regulatory changes are expected to benefit future product approvals.
Fiscal Year 2024
-
2024 saw revenue decline 15% to CAD 8M amid funding and inventory challenges, but decisive cost reductions and expanded retail distribution set the stage for improved margins and growth in 2025. Strategic focus includes new product launches, European manufacturing, and regulatory progress.